BD, also known as Becton, Dickinson and Co., said Thursday that it acquired Tissuemed, a privately held firm headquartered in Leeds, England, that is an industry leader in developing self-adhesive surgical sealant films.
The acquisition expands the Franklin Lakes-based company’s global offerings for surgeons outside of the U.S.
Tissuemed’s lead product, Tissuepatch, is a proprietary sealant technology that bonds to tissue to help control internal bleeding or prevent leaks from surgical incisions. The technology’s thin, flexible and transparent composition that is ready to use out of the package makes it ideally suited for a range of surgical sealant applications.
“This advanced sealant serves as a strategic complement to the BD products used in the operating room today — providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions,” said Kevin Kelly, president of surgery for BD. “Integrating Tissuepatch into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries.”
Tissuepatch is already trusted among surgeons due to its design, which enables strong adhesive and minimal swelling. This foundation provides BD with an opportunity to leverage its reach and clinical expertise to continue to innovate within the sealant technology category, which is expected to grow significantly over the next five to 10 years.
Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD’s fiscal 2022 financial results.